Minoxidil
- Generic Name
- Minoxidil
- Brand Names
- Loniten, Minox, Regoxidine, Rogaine
- Drug Type
- Small Molecule
- Chemical Formula
- C9H15N5O
- CAS Number
- 38304-91-5
- Unique Ingredient Identifier
- 5965120SH1
- Background
A potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure.
- Indication
For the treatment of severe hypertension and in the topical treatment (regrowth) of androgenic alopecia in males and females and stabilisation of hair loss in patients with androgenic alopecia.
- Associated Conditions
- Androgenetic Alopecia (AGA), Severe, symptomatic Hypertension
Bioavailability Clinical Trial of Oral Minoxidil 1 mg
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2023-08-29
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Industrial Farmacéutica Cantabria, S.A.
- Target Recruit Count
- 14
- Registration Number
- NCT06015516
- Locations
- 🇪🇸
Hospital Universitario de la Princesa, Madrid, Spain
Effectiveness of Combination Therapy of Microneedling and Minoxidil in Androgenetic Alopecia of Indonesian Men
Phase 3
Completed
- Conditions
- Androgenetic Alopecia
- Interventions
- Device: microneedling
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Indonesia University
- Target Recruit Count
- 36
- Registration Number
- NCT05989165
- Locations
- 🇮🇩
Cipto Mangungkusumo Hospital, Jakarta, DKI Jakarta, Indonesia
Effectiveness and Safety of Topical Finasteride and Minoxidil Combination Compared to Topical Minoxidil for The Treatment of Male Androgenetic Alopecia
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- Indonesia University
- Target Recruit Count
- 40
- Registration Number
- NCT05990400
- Locations
- 🇮🇩
University Indonesia, Jakarta, Other (Non U.s.), Indonesia
Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia
Phase 3
Not yet recruiting
- Conditions
- Female Pattern BaldnessAndrogenetic Alopecia
- Interventions
- First Posted Date
- 2023-06-05
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Industrial Farmacéutica Cantabria, S.A.
- Target Recruit Count
- 520
- Registration Number
- NCT05888922
Phase I Study of Safety and Pharmacokinetics of Topical Solution in Subjects With Androgenetic Alopecia
- First Posted Date
- 2023-05-18
- Last Posted Date
- 2023-05-18
- Lead Sponsor
- Aneira Pharma, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT05864885
A Study of Oral Minoxidil to Treat Hair Loss in Children, Teens, and Young Adults Who Are Cancer Survivors
Phase 2
Recruiting
- Conditions
- Survivors of Childhood CancerAlopecia
- Interventions
- Other: Placebo
- First Posted Date
- 2023-03-21
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT05778825
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Safety and Efficacy Study of Topical DLQ01 in the Treatment of Androgenetic Alopecia (AGA) in Men
Phase 1
Completed
- Conditions
- Androgenetic Alopecia
- Interventions
- Drug: prostaglandin F2a analogue in vehicle solution high doseDrug: prostaglandin F2a analogue in vehicle solution low doseDrug: active ingredient-free vehicle solution to DLQ01
- First Posted Date
- 2022-12-05
- Last Posted Date
- 2024-04-08
- Lead Sponsor
- Dermaliq Therapeutics, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT05636904
- Locations
- 🇦🇺
Dr Rodney Sinclair Pty Ltd,, Pascoe Vale South, Victoria, Australia
Role of Minoxidil in Alopecia Areata Transepidermal Drug Delivery of Minoxidil Via Either Fractional Carbon Dioxide Laser or Microneedling Versus Its Topical Nanoparticles Preparation for Treatment of Alopecia Areata
Not Applicable
Not yet recruiting
- Conditions
- Alopecia Areata
- Interventions
- First Posted Date
- 2022-10-20
- Last Posted Date
- 2022-10-20
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 60
- Registration Number
- NCT05587257
Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Cancer
Early Phase 1
Recruiting
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Endocrine Therapy-Induced AlopeciaAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Prognostic Stage IIA Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Prognostic Stage I Breast Cancer AJCC v8Prognostic Stage IA Breast Cancer AJCC v8
- Interventions
- First Posted Date
- 2022-06-14
- Last Posted Date
- 2025-04-04
- Target Recruit Count
- 50
- Registration Number
- NCT05417308
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Comparison Between Efficacy of Topical Sildenafil 2% and Topical Minoxidil 5% in Treatment of Androgenic Alopecia
- First Posted Date
- 2022-05-11
- Last Posted Date
- 2022-05-11
- Lead Sponsor
- Mohammed Abd El Mawgoud Amer
- Target Recruit Count
- 50
- Registration Number
- NCT05369481
- Locations
- 🇪🇬
AL-Azhar University Hospital, Cairo, Egypt
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath